Huperzine A for Managing and Treating Dementia

View at publisher Summarise with VIRAT
Authors: Olatoun Motunrayo Olutunde, Kehinde Oluwaseyi Adeniji, Abosede Mary Ayoola, Anne Fiyinfoluwa Sanwo, David Temidayo Ovioke, Victor Bassey Archibong, Rhoda Mama Kolo, Onyema Kelechi Roselyn, Dada Moyosoluwa Mary, Temitope Oluwatobi Adeniji
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Dementia is a progressive brain disorder. It is currently being treated with acetylcholinesterase inhibitors (AChEIs), which offer symptomatic relief but often cause adverse effects and do not modify disease progression. This chapter examines Huperzine A ( HupA ), a natural alkaloid from Huperzia serrata , as a potential therapeutic agent. HupA is a potent, selective, and reversible AChEI, and its bioavailability and blood–brain barrier penetration are higher than those of standard drugs. Beyond its cholinergic action, it exhibits multi-target neuroprotective effects, including anti-apoptotic, antioxidant, and antiamyloid properties. Evidence from clinical studies shows that HupA offers cognitive improvements in patients with Alzheimer's disease and vascular dementia with a favorable safety profile. However, study quality, regulatory status, and sustainable sourcing challenges remain. Future directions require large-scale, long-term trials and advanced delivery systems to fully integrate HupA into mainstream dementia therapy.

Fields of Study & Subjects

Cholinesterase and Neurodegenerative Diseases Alzheimer's disease research and treatments Medicinal Plants and Neuroprotection

Publication details

Journal / source
CRC Press eBooks
Pages
58–69
Publication date
31 March 2026
Language
EN
Document type
Book chapter